Medicare & Medicaid
Negotiations with participating drug companies will occur in 2023 and 2024, and prices will become effective beginning in 2026.
ACOs that earned shared savings tended to be low revenue small and rural hospitals or organizations made up of physicians.
Authors say MA growth means insurers are increasingly attempting to curtail inefficient use of post-acute care services.
The lawsuit alleges that the Medicaid redeterminations began a month before they were allowed under federal legislation.
On or before September 1, CMS will release the names of the 10 Part D drugs subject to negotiated prices starting in 2026.
The new program would allow for monthly payments over a year.
Select says the plan offerings will increase access to options and services that promote health and wellness.
A strong majority also agrees that future generations will have to pay more or accept reduced benefits.
Episode-based payment incentives must be aligned across other value-based models, CMS says.
HCSC will offer MA and/or Medicare Advantage Prescription Drug plans in more than 82% of counties in the states it serves.